The Australian Government Simplifies the Clinical Eligibility Criteria for the Continuous Glucose Monitoring (CGM) Initiative – AMSL Diabetes


The Australian Government Simplifies the Clinical Eligibility Criteria for the Continuous Glucose Monitoring (CGM) Initiative

The Australian Government Simplifies the Clinical Eligibility Criteria for the Continuous Glucose Monitoring (CGM) Initiative

Sydney, Australia, March 2020

The Australian Government is simplifying the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative from the 1st of March, 2020. This will allow people with type 1 diabetes under the age of 21, and those over the age of 21 who have valid concessional status to access fully subsidised CGM devices through the National Diabetes Services Scheme (NDSS).

Both Dexcom G5 Mobile and Dexcom G4 PLATINUM Systems are available to eligible patients who meet the new eligibility criteria for one of the following groups:

  • Children and young people under 21 years with type 1 diabetes
  • People with type 1 diabetes aged 21 years or older who have valid concessional status
  • Children and young people under 21 years with conditions very similar to type 1 diabetes who require insulin, such as cystic fibrosis-related diabetes and neonatal diabetes.

Patients or healthcare professionals can visit our website for more information, or visit NDSS at www.ndss.com.au/CGM.

The Australian Government Simplifies the Clinical Eligibility Criteria for the Continuous Glucose Monitoring (CGM) Initiative

Stay informed with AMSL Diabetes

Now you can get all the latest news and updates of our products, events and resources right into your inbox.

Something went wrong. Please try again later!

Send AMSL Diabetes a message

We are always happy to help, send us a message or enquiry

Shopping cart

Subtotal
Shipping and discount codes are added at checkout.
Checkout
Back to top